drugset / Trial / NCT00506701

Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension

NCT00506701

Withdrawn Herlev Hospital
NaSingle-groupTriple-blindTreatment

Summary

Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.

Timeline

Start
2008-02
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 40 mg